Pyrrolinidium derivatives as M3 muscarinic receptors

Details for Australian Patent Application No. 2005318423 (hide)

Owner Novartis AG

Inventors Collingwood, Stephen Paul; Press, Neil John

Agent Davies Collison Cave

Pub. Number AU-B-2005318423

PCT Pub. Number WO2006/066928

Priority 0428416.2 24.12.04 GB

Filing date 22 December 2005

Wipo publication date 29 June 2006

Acceptance publication date 3 December 2009

International Classifications

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/4025 (2006.01) - not condensed and containing further heterocyclic rings, e.g. cromakalim

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

28 June 2007 PCT application entered the National Phase

  PCT publication WO2006/066928 Priority application(s): WO2006/066928

3 December 2009 Application Accepted

  Published as AU-B-2005318423

1 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005318424-Quaternary ammonium salts as M3 antagonists

2005318419-Azole derivatives with antimuscarinic activity